



National Kidney
Foundation®

30 East 33rd Street
New York, NY 10016
800.622.9010
www.kidney.org

Nonprofit
US Postage Paid
National
Kidney
Foundation



Free Interactive Case-Based
CME/CE Learning Activity

Protecting the Kidney in People
with Type 2 Diabetes:
Case Simulations to Improve
Real Outcomes

© 2011 National Kidney Foundation, Inc. All rights reserved. 02:10-4438_JBB



A FREE Interactive Case-Based CME/CE Learning Protecting the Kidney in People with Type 2 Diabetes: Case Simulations to Improve Real Outcomes

Interactive cases will allow learners to diagnose and treat virtual patients using a multifactorial and multidisciplinary approach to managing type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) stages 1–4.

Register at
www.kidney.org/CME

Release Date: December 20, 2011
Expiration Date: December 20, 2013

Accredited by



Supported by an educational grant from



Target Audience

- Physicians (nephrologists, endocrinologists, cardiologists, family physicians)
- Physician assistants
- Nurse practitioners
- Nurses
- Dietitians
- Pharmacists

Overview

The coexistence of diabetes and chronic kidney disease presents a significant health, social, and economic burden and negatively influences health status beyond the sum of the effects of each disease. This interactive, web-based, virtual patient CME/CE activity will focus on the importance of timely evaluation and management of chronic kidney disease (CKD) stages 1–4 in patients with type 2 diabetes mellitus (T2DM). Interactive cases will allow learners to diagnose and treat patients using a multifactorial and multidisciplinary approach in a virtual setting. Its goal is improved patient outcomes related to T2DM and CKD.

Learning Objectives

After completing this educational activity, you will be able to:

- Apply the screening guidelines for diabetes and chronic kidney disease (CKD) in populations at risk to identify these diseases at an earlier stage, in order to prevent or slow complications
- Integrate evidence-based guidelines in complicated patients with multiple chronic diseases to develop clinical action plans designed to prevent or minimize adverse long-term outcomes
- Use evidence-based intervention in patients who have diabetes, cardiovascular disease risks, and CKD to stabilize these conditions, slow the deterioration in glomerular filtration rate (GFR), and delay the onset of end-stage renal disease (ESRD)
- Institute team care for patients with diabetes to control risk factors, screen for complications, improve follow up care, appropriately refer to specialists, and provide access to supportive clinical resources

Topics

- Introduction
 - Microalbuminuria
 - Managing CKD and CVD Risk in Patients with T2DM
 - HbA1c Targets in Diabetes and CKD
 - Hypoglycemia
 - Hyperglycemic Agents for Patients with Diabetes and CKD
- Virtual Patient Presentations
 - T2DM, dyslipidemia, albuminuria, family history of end-stage renal disease
 - T2DM, hypertension, anemia, CKD stage 4
 - T2DM, hypertension, obesity, family history of CKD and CVD
- Suggested Reading

Faculty

Luiza Caramori, MD, MS, PhD

Assistant Professor
Division of Endocrinology and Diabetes
University of Minnesota
Minneapolis, MN

Sue Cary, BSN, MN, APRN, NP-BC, CNN

Nurse Practitioner
Ochsner Healthcare System
Baton Rouge, LA

Adrianna Hung, MD, MPH

Assistant Professor of Medicine
Division of Nephrology, Department of Medicine
Vanderbilt University School of Medicine
Nashville, TN

Maya Rao, MD

Assistant Professor of Clinical Medicine
Division of Nephrology
Columbia University Medical Center
New York, NY

Accreditation

Physician

The National Kidney Foundation is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The National Kidney Foundation designates this Enduring Material for a maximum of 1.5 *AMA PRA Category 1 Credits*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This Enduring Material activity, “Protecting the Kidney in People with Type 2 Diabetes: Case Simulations to Improve Real Outcomes,” has been reviewed and is acceptable for up to 1.50 Prescribed credit(s) by the American Academy of Family Physicians. AAFP accreditation begins December 20, 2011. Term of approval is for two years from this date with the option of yearly renewal. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistant

AAPA accepts certificates of participation for educational activities certified for Category I credit from AOACCME, Prescribed credit from AAFP, and *AMA PRA Category 1 Credit(s)*[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.5 hours of Category I credit for completing this program.

Nurse Practitioner

This program has been approved for 1.5 contact hours of continuing education (which includes 0.30 hour of pharmacology) by the American Academy of Nurse Practitioners. Program ID 111378.

This program was planned in accordance with AANP CE Standards and Policies and AANP Commercial Support Standards.

Nurse

The National Kidney Foundation is an approved provider of continuing nursing education by the New York State Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.

It has been assigned Provider code 7QPLGU-PRV-09.

1.5 contact hours will be awarded.

Dietitian



The National Kidney Foundation is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered Dietitians (RDs) and Dietetic Technicians, Registered (DTRs) will receive 1.5 continuing professional education units (CPEUs) for completion of this program/material.

Pharmacist



The University of Illinois at Chicago College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of pharmacy continuing education. Completion of the entire knowledge-based activity, post-test questions, and evaluation are prerequisites for receiving a statement of continuing pharmacy education credit for 1.5 contact hours (0.15 CEUs). You will receive your statement of credit immediately upon successful completion of the CPE activity. This activity has been assigned ACPE Universal Activity Number 0016-999-11-160-H01P.

Method of Participation

This CME/CE activity is available as a dynamic web-based, computer-guided experience that allows learners to assess the needs of three virtual patients similar to challenging patients whom they see in practice. A complete picture of each “virtual patient” will be unveiled as the clinician reads the patient record, asks questions, and elicits findings from laboratory data and physical exams. Once the learners feel confident about the information, they will be able to develop a clinical action plan that addresses individual virtual patient needs, including those for collaborative inter-professional care. Upon submission of the clinical action plan, learners will be able to compare their clinical action plans against an evidence-based “best practice” plan outlined in advance by clinical experts.

To receive a certificate of completion, participants will be required to complete, at a minimum, one virtual patient experience, including a post-test and program evaluation. The estimated time for completion is 1.5 hours. To receive *AMA PRA Category 1 Credit(s)*[™], participants must receive a minimum score of 70% on the post-test.

Declaration of Disclosure

It is the policy of the National Kidney Foundation (NKF) to ensure balance, independence, objectivity, and scientific rigor in all CME/CE activities. Any individual who has control over CME content is required to disclose to learners prior to the activity any relevant financial relationship(s) they may have with commercial interests supporting this activity or whose products or devices are discussed in this activity. If, on the basis of information disclosed, a perceived conflict exists, resolution will be achieved based on NKF's Disclosure and Conflict of Interest Policy.

Unlabeled/Investigational Use

During their presentations, faculty may discuss an unlabeled use or an investigational use not approved for a commercial product. Each faculty member is required to disclose this information to the audience when referring to an unlabeled or investigational use.

Disclaimer

The faculty, National Kidney Foundation, and Boehringer Ingelheim do not recommend the use of any pharmaceutical, diagnostic test, or device outside of the labeled indications as approved by the FDA. Please refer to the official prescribing information for each product for approved indications, contraindications, and warnings.